Capital City Trust Co. FL Has $7.52 Million Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Posted by Defense World Staff on Apr 16th, 2023

Capital City Trust Co. FL lifted its position in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 0.2% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 42,584 shares of the company’s stock after acquiring an additional 89 shares during the period. Johnson & Johnson accounts for 2.5% of Capital City Trust Co. FL’s portfolio, making the stock its 4th biggest holding. Capital City Trust Co. FL’s holdings in Johnson & Johnson were worth $7,522,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of JNJ. Glassy Mountain Advisors Inc. bought a new position in Johnson & Johnson in the 4th quarter valued at about $35,000. Retirement Financial Solutions LLC acquired a new stake in Johnson & Johnson in the 4th quarter valued at about $40,000. TD Capital Management LLC acquired a new stake in Johnson & Johnson in the 3rd quarter valued at about $48,000. Iron Horse Wealth Management LLC lifted its holdings in Johnson & Johnson by 112.8% in the 4th quarter. Iron Horse Wealth Management LLC now owns 300 shares of the company’s stock valued at $53,000 after acquiring an additional 159 shares during the last quarter. Finally, Cowa LLC acquired a new stake in Johnson & Johnson in the 3rd quarter valued at about $58,000. Institutional investors own 67.94% of the company’s stock.

Insider Buying and Selling

In related news, insider James D. Swanson sold 1,062 shares of the stock in a transaction that occurred on Monday, March 6th. The stock was sold at an average price of $154.66, for a total value of $164,248.92. Following the transaction, the insider now owns 9,215 shares in the company, valued at $1,425,191.90. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.20% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on JNJ shares. SVB Leerink cut their price target on shares of Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating for the company in a report on Friday, January 20th. Piper Sandler cut their price target on shares of Johnson & Johnson from $55.00 to $52.00 in a report on Monday, February 6th. Atlantic Securities upped their price target on shares of Johnson & Johnson from $160.00 to $168.00 and gave the company a “neutral” rating in a report on Wednesday, January 25th. Morgan Stanley reduced their price objective on shares of Johnson & Johnson from $180.00 to $179.00 and set an “equal weight” rating for the company in a research note on Monday, April 10th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, February 1st. Seven analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $173.07.

Johnson & Johnson Price Performance

Shares of JNJ opened at $165.84 on Friday. The company has a market capitalization of $431.90 billion, a price-to-earnings ratio of 24.61, a P/E/G ratio of 2.83 and a beta of 0.53. Johnson & Johnson has a fifty-two week low of $150.11 and a fifty-two week high of $186.69. The company has a debt-to-equity ratio of 0.35, a current ratio of 0.99 and a quick ratio of 0.77. The business’s 50-day moving average is $157.46 and its 200-day moving average is $167.02.

Johnson & Johnson (NYSE:JNJ – Get Rating) last issued its earnings results on Tuesday, January 24th. The company reported $2.35 earnings per share for the quarter, beating analysts’ consensus estimates of $2.22 by $0.13. The company had revenue of $23.71 billion for the quarter, compared to the consensus estimate of $23.90 billion. Johnson & Johnson had a return on equity of 35.76% and a net margin of 18.90%. The firm’s quarterly revenue was down 4.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.13 EPS. Equities research analysts expect that Johnson & Johnson will post 10.49 EPS for the current fiscal year.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.